文献速递肿瘤 PET/CT神经核医学

胰腺尾部神经内分泌肿瘤误判为肾癌转移:68Ga-LNC1007 PET/CT病例

Mimicking Metastatic Renal Cell Carcinoma: A Case of Pancreatic Tail Neuroendocrine Neoplasm on 68Ga-LNC1007 PET/CT.
PubMed 文献 · Clin Nucl Med · 2026-04-01

一例79岁有肾细胞癌病史的患者因上腹部非特异性疼痛就诊,增强CT和MRI未显示明确恶性证据,68Ga-LNC1007(68Ga-FAPI-RGD)PET/CT发现胰腺尾部放射性摄取显著增高灶,最初判读为肾细胞癌转移,手术病理证实为神经内分泌肿瘤。该病例提示神经内分泌肿瘤可被常规影像漏诊或误判为其他恶性肿瘤,并显示68Ga-LNC1007 PET/CT对该类肿瘤的潜在诊断价值。

要点

  • 有肾细胞癌病史者出现胰腺局灶性高摄取时,需将神经内分泌肿瘤纳入鉴别。
  • 常规增强CT和MRI可漏诊神经内分泌肿瘤,68Ga-LNC1007 PET/CT可能提供补充诊断信息。
  • 影像判读应结合病史与病理,避免将功能性摄取灶简单归因于已知原发肿瘤转移。

核心结论

  • 胰腺尾部神经内分泌肿瘤可表现为68Ga-LNC1007 PET/CT高摄取灶,并被误判为肾细胞癌转移。

研究设计与样本

  • 单例病例报告:79岁有肾细胞癌病史的患者,因6个月前出现非特异性上腹痛就诊。

主要发现

  • 增强CT和MRI未显示明确的恶性证据。
  • 68Ga-LNC1007(68Ga-FAPI-RGD)PET/CT显示胰腺尾部放射性摄取显著增高灶,最初判读为肾细胞癌转移。
  • 手术病理证实该病灶为神经内分泌肿瘤(NEN)。

临床怎么用

  • 对常规影像阴性但有症状的肾细胞癌病史患者,可考虑68Ga-LNC1007 PET/CT辅助寻找病灶。
  • 胰腺局灶性高摄取在判读为转移前,应结合临床与病理鉴别神经内分泌肿瘤。

局限性

  • 单例病例报告,结论的外推性有限;原文未报告定量摄取参数、随访时间及更多临床细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 79-year-old patient with a history of renal cell carcinoma (RCC) presented with nonspecific upper abdominal pain 6 months ago. Contrast-enhanced CT and MRI did not reveal definitive evidence of malignancy. However, 68Ga-LNC1007 (68Ga-FAPI-RGD) PET/CT demonstrated a significant radiotracer-avid focus in the tail of the pancreas, initially interpreted as a metastatic RCC lesion. Surgical pathology later confirmed the lesion as a neuroendocrine neoplasm (NEN). This case illustrates that neuroendocrine tumors may occasionally be missed by conventional imaging modalities or suspected as other malignancies in certain scenarios, and highlights the potential diagnostic value of 68Ga-LNC1007 PET/CT in detecting neuroendocrine tumors.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zang J, Peng Y, Liu Q, et al. Mimicking Metastatic Renal Cell Carcinoma: A Case of Pancreatic Tail Neuroendocrine Neoplasm on 68Ga-LNC1007 PET/CT. Clin Nucl Med. 2026. PMID: 41921938. doi:10.1097/RLU.0000000000006385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。